Table 1.

Overview of the use of the PBPK/PD QSP approach

ID	Applied drug(s)	Pharmacological action	Results	Fig.
1	CEL	Single COX-2 inhibition	Drug efficacy	4a
2	DFN	Single COX-2 inhibition	Drug efficacy	4a
3	RIF + CEL	Single COX-2 inhibition	PK drug interaction and impact on drug efficacy	4a
4	RIF + DFN	Single COX-2 inhibition	PK drug interaction and impact on drug efficacy	4a
5	LCF	Dual COX-2/5-LOX inhibition	Drug efficacy	4b
6	CEL + ZLT	Single COX-2/Single 5-LOX inhibition	Drug efficacy	4b
7	DFN + ZLT	Single COX-2/Single 5-LOX inhibition	Drug efficacy	4b
8	DFN	Single COX-2 inhibition	Correlation of prostaglandin decrease and pain relief	5a
9	CEL	Single COX-2 inhibition	Correlation of prostaglandin decrease and pain relief	5b
10	RIF + DFN	Single COX-2 inhibition	Comparison of observed and predicted PK drug interaction	6a
			PK drug interaction and impact on prostaglandin formation	6d
11	RIF + CEL	Single COX-2 inhibition	Comparison of observed and predicted PK drug interaction	6a
			PK drug interaction and impact in prostaglandin formation	6d

Applications of the PBPK/PD QSP approach including the applied drugs, the pharmacological action and the main results illustrated in the correspondent figure. Celecoxib, CEL; diclofenac, DFN; licofelone, LCF; rifampicin, RIF; zileuton, ZLT; cyclooxygenase, COX; lipoxygenase, LOX